Heart rate recovery, cardiac rehabilitation, and erectile dysfunction in males with ischemic heart disease

To the Editor,

I have read the article entitled “Heart rate recovery, cardiac rehabilitation, and erectile dysfunction in males with ischemic heart disease” by Kalka et al. (1) with great interest, which was recently published in Anatolian Journal of Cardiology 2016; 16: 256-63. The investigators reported that in patients with ischemic heart disease (IHD) and erectile dysfunction (ED) subjected to cardiac rehabilitation, enhancement of autonomic balance assessed using heart rate recovery (HRR) plays a significant role in the mechanism of improvement in erection quality (1). Authors have reported that there was no significant difference with regard to beta-blocker therapy (1).

Beta-blockers are one of the most commonly used and cornerstone therapy in the treatment of ischemic heart disease (2). Nebivolol is a third-generation beta-blocker, and has a vasodilating effect that is attributed to the generation of endothelial nitric oxide, in addition to β1-adrenoceptor selectivity (3).

It is well known that beta-blocker therapy effect might be different with regard to ED depending on sort of it in patients with IHD (4). Aldemir et al. (4) have reported that although ED in males undergoing CABG surgery decreases when metoprolol is used, nebivolol had a protective effect on the sexual activity of men undergoing coronary artery bypass surgery with cardiopulmonary bypass. In addition, Brixius et al. (5) have reported beneficial effects of nebivolol on the erectile function in hypertensive men.

I would like to emphasize one important point to clarify in this article. Kind of beta-blocker therapy is very important to evaluate ED in patients with IHD (3–5). Therefore, authors should mention kind of beta-blocker therapy used in this study group.

In conclusion, ED is more common in men with IHD. Nebivolol, a third-generation beta-blocker, seems to have beneficial effects on ED compared with metoprolol (3–5). Kind of beta-blocker therapy might affect ED in patients with IHD.

Zeynettin Kaya
Department of Cardiology, Faculty of Medicine, Mevlana University; Konya-Turkey

References


Address for Correspondence: Dr. Zeynettin Kaya
Mevlana Üniversitesi Tıp Fakültesi, Kardiyojoloji Bölümü
Yeni İstanbul Cad. No: 235
42003 Selçuklu/Konya-Türkiye
E-mail: zeynettinkaya@yahoo.com

Heart rate recovery, cardiac rehabilitation, and erectile dysfunction in males with ischemic heart disease

To the Editor,

I have read the article entitled “Heart rate recovery, cardiac rehabilitation, and erectile dysfunction in males with ischemic heart disease” by Kalka et al. (1) with great interest, which was recently published in Anatolian Journal of Cardiology 2016; 16: 256-63. The investigators reported that in patients with ischemic heart disease (IHD) and erectile dysfunction (ED) subjected to cardiac rehabilitation, enhancement of autonomic balance assessed using heart rate recovery (HRR) plays a significant role in the mechanism of improvement in erection quality (1). Authors have reported that there was no significant difference with regard to beta-blocker therapy (1).

Beta-blockers are one of the most commonly used and cornerstone therapy in the treatment of ischemic heart disease (2). Nebivolol is a third-generation beta-blocker, and has a vasodilating effect that is attributed to the generation of endothelial nitric oxide, in addition to β1-adrenoceptor selectivity (3).

It is well known that beta-blocker therapy effect might be different with regard to ED depending on sort of it in patients with IHD (4). Aldemir et al. (4) have reported that although ED in males undergoing CABG surgery decreases when metoprolol is used, nebivolol had a protective effect on the sexual activity of men undergoing coronary artery bypass surgery with cardiopulmonary bypass. In addition, Brixius et al. (5) have reported beneficial effects of nebivolol on the erectile function in hypertensive men.

I would like to emphasize one important point to clarify in this article. Kind of beta-blocker therapy is very important to evaluate ED in patients with IHD (3–5). Therefore, authors should mention kind of beta-blocker therapy used in this study group.

In conclusion, ED is more common in men with IHD. Nebivolol, a third-generation beta-blocker, seems to have beneficial effects on ED compared with metoprolol (3–5). Kind of beta-blocker therapy might affect ED in patients with IHD.

Zeynettin Kaya
Department of Cardiology, Faculty of Medicine, Mevlana University; Konya-Turkey

Reference


Address for Correspondence: Dr. Zeynettin Kaya
Mevlana Üniversitesi Tıp Fakültesi, Kardiyojoloji Bölümü
Yeni İstanbul Cad. No: 235
42003 Selçuklu/Konya-Türkiye
E-mail: zeynettinkaya@yahoo.com
Letters to the Editor

Levent Cerit
Department of Cardiology, Near East University; Nicosia-Turkish Republic of Northern Cyprus

References


Address for Correspondence: Dr. Levent Cerit
Near East Hospital University Hospital
Nicosia-Turkish Republic of Northern Cyprus
Phone: +90 392 675 10 00  E-mail: drcerit@hotmail.com
©Copyright 2016 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.com
DOI:10.14744/AnatolJCardiol.2016.7229

Author’s Reply

To the Editor,

We thank the author(s) for their constructive comments on our study entitled “Heart rate recovery, cardiac rehabilitation, and erectile dysfunction in males with ischemic heart disease” published in the Anatolian Journal of Cardiology 2016; 16: 256-63 (1). In our study, we aimed to assess the relationship between heart rate recovery and the severity of erectile dysfunction (ED) in patients with ischemic heart disease and ED who have undergone cardiac rehabilitation. In addition, we assessed the impact of pharmacotherapy on the severity of ED among others. We are glad to learn that pharmacotherapy of ED and concomitant diseases are interesting because this can improve the overall quality of life in patients with many coexisting disorders.

Indeed nebivolol has unique properties when compared with previous generation beta-blockers. Nebivolol is approximately 3.5 times more cardio selective than bisoprolol, which reduces the risk of side effects typical for other beta-blockers (2). Another advantage of nebivolol is its vasodilator effect due to the increase of endogenous nitric oxide release by the endothelial cells, which leads us to hypothesize about the potentially antiatherogenic effect of this drug and creates the premise that nebivolol could also be beneficial in patients with ischemic heart disease (3); however, at present, it is not approved for the treatment of ischemic heart disease without coexisting arterial hypertension or heart failure (4).

In the erection mechanisms, endothelium-dependent relaxation of the penile arteries is crucial because rapid increase of their capacity up to 80% allows for bringing sufficient volume of blood to initiate the corporal veno-occlusive mechanism and maintain erection (5). The unique effect of nebivolol on the endothelium improves vessel relaxation, and in contrast to other beta-adrenergic blocking agents, nebivolol does not impair sexual function. In males with hypertension and coronary artery disease invasively treated, nebivolol had a protective effect on sexual function (2, 6).

In our study, beta-blockers were taken by 84 (94.38%) patients. Their use had no significant influence on the initial IIEF-5 (EQ1) score, as well as their change (Δ EQ) caused by cardiac training (1). We agree that the comparison of nebivolol with other beta-blockers could bring additional information, but the small percentage of patients on nebivolol vs. bisoprolol, metoprolol, and carvedilol would not guarantee reliable results. At the time of the study, patients used to choose other drugs because of economic reasons. This situation has changed as the introduction of generics improved the availability of nebivolol for more male patients than before and allowed them to benefit from the unique properties of this drug in terms of sexual function.

Dariusz Kalka1,2
1Cardiosexology Unit, Department of Pathophysiology, Wrocław Medical University; ul. K. Marcinkowskiego 1; Wrocław-Poland
2Centre for Men’s Health in Wrocław-Poland

References